Iovance Biotherapeutics Inc (IOVA) concluded trading on Wednesday at a closing price of $5.65, with 6.62 million shares of worth about $37.38 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -46.19% during that period and on February 19, 2025 the price saw a gain of about 1.62%. Currently the company’s common shares owned by public are about 304.62M shares, out of which, 244.54M shares are available for trading.
Stock saw a price change of 6.81% in past 5 days and over the past one month there was a price change of -4.40%. Year-to-date (YTD), IOVA shares are showing a performance of -23.65% which decreased to -42.76% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.05 but also hit the highest price of $18.33 during that period. The average intraday trading volume for Iovance Biotherapeutics Inc shares is 7.43 million. The stock is currently trading -2.75% below its 20-day simple moving average (SMA20), while that difference is down -16.07% for SMA50 and it goes to -36.64% lower than SMA200.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) currently have 304.62M outstanding shares and institutions hold larger chunk of about 70.47% of that.
The stock has a current market capitalization of $1.72B and its 3Y-monthly beta is at 0.88. It has posted earnings per share of -$1.50 in the same period. It has Quick Ratio of 3.90 while making debt-to-equity ratio of 0.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IOVA, volatility over the week remained 5.64% while standing at 5.94% over the month.
Stock’s fiscal year EPS is expected to rise by 31.48% while it is estimated to increase by 32.78% in next year. EPS is likely to grow at an annualized rate of 45.45% for next 5-years, compared to annual growth of -8.25% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on October 24, 2024 offering a Buy rating for the stock and assigned a target price of $17 to it. Coverage by Piper Sandler stated Iovance Biotherapeutics Inc (IOVA) stock as a Neutral in their note to investors on July 29, 2024, suggesting a price target of $10 for the stock. On November 20, 2023, Goldman Initiated their recommendations, while on September 18, 2023, Barclays Reiterated their ratings for the stock with a price target of $18. Stock get an Overweight rating from Wells Fargo on May 30, 2023.
